Docetere 20 mg/1 mL RTU, 80 mg/4 mL RTU Concentrate for solution for infusion
PDF Leaflet Revision Date: 03 October 2022
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of various cancers including breast, lung, ovarian, prostate, head and neck, and gastric cancers.
Dosage (summary)
75 mg/mu00b2 every 3 weeks; 100 mg/mu00b2 for monotherapy.
Onset of Action / Duration
Onset: 7 days, Duration: variable
Special Populations
- Hepatic impairment
- Elderly
- Children
Pregnancy & Breastfeeding
Contraindicated; teratogenic in animals.
Key Drug Interactions
- Strong CYP3A4 inhibitors
- Dexamethasone
Contraindications
- Severe hypersensitivity to docetaxel
- Neutrophil count < 1500 cells/mmu00b3
- Severe liver impairment
Common side effects
- Neutropenia
- Hypersensitivity reactions
- Fluid retention
- Nausea
- Alopecia
Counselling Points
- Monitor for signs of hypersensitivity
- Avoid pregnancy during treatment
- Inform about potential side effects
Serious warnings
- Severe hypersensitivity reactions
- Increased risk of neutropenia
- Fluid retention
- Potential for second malignancies
Important Disclaimer
The Docetere 20 mg/1 mL RTU, 80 mg/4 mL RTU Concentrate for solution for infusion professional information leaflet below is the property of Sanofi-Aventis South Africa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
